Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,430.00GBp
20 Apr 2018
Change (% chg)

22.60 (+1.61%)
Prev Close
1,407.40
Open
1,419.00
Day's High
1,435.00
Day's Low
1,414.20
Volume
8,747,041
Avg. Vol
9,888,715
52-wk High
1,724.50
52-wk Low
1,235.20

Latest Key Developments (Source: Significant Developments)

GSK To Transfer Rare Disease Gene Therapy Portfolio To Orchard Therapeutics
Thursday, 12 Apr 2018 

April 12 (Reuters) - GlaxoSmithKline PLC ::GSK SIGNS STRATEGIC AGREEMENT TO TRANSFER RARE DISEASE GENE THERAPY PORTFOLIO TO ORCHARD THERAPEUTICS.GSK TAKES 19.9 PCT EQUITY STAKE IN ORCHARD AND SEAT ON BOARD.GSK TO RECEIVE FINANCIAL CONSIDERATIONS IN FORM OF ROYALTIES AND COMMERCIAL MILESTONE PAYMENTS RELATED TO ACQUIRED PORTFOLIO.BOTH COS AGREED TO A TRANSITION PERIOD DURING WHICH GSK WILL CONTINUE TO CONDUCT CERTAIN ACTIVITIES THROUGH TO END OF 2018.ORCHARD TO ASSUME OBLIGATIONS ARISING FROM GSK'S 2010 COLLABORATION AGREEMENT WITH OSPEDALE SAN RAFFAELE, FONDAZIONE TELETHON.ORCHARD TO ALSO ASSUME ALL OBLIGATIONS ARISING FROM GSK'S COLLABORATION AGREEMENT WITH MOLMED.  Full Article

GlaxoSmithKline Inc Says Trelegy Ellipta Approved In Canada
Thursday, 5 Apr 2018 

April 5 (Reuters) - GlaxoSmithKline Inc::TRELEGY ELLIPTA APPROVED IN CANADA AS FIRST INHALER FOR LONG-TERM, ONCE DAILY TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE .TRELEGY ELLIPTA AVAILABILITY IS EXPECTED JUNE 2018.  Full Article

GSK Receives FDA Approval For Expanded Indication For Fluarix
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Glaxosmithkline Plc ::GSK RECEIVES FDA APPROVAL FOR EXPANDED INDICATION FOR FLUARIX® QUADRIVALENT (INFLUENZA VACCINE) FOR PERSONS 6 MONTHS AND OLDER.  Full Article

GSK CEO Says No Expected Dividend Increase In Near Term
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Glaxosmithkline Plc ::GSK CEO SAYS WILL TAKE TIME TO BUILD REIMBURSEMENT FOR SHINGRIX SHINGLES VACCINE.GSK CEO SAYS HAS NO DOUBT SHINGRIX CAN BE COMPANY'S MOST LUCRATIVE VACCINE.GSK CEO SAYS NO CHANGE TO DIVIDEND POLICY LAID OUT LAST YEAR.GSK CEO SAYS NO EXPECTED DIVIDEND INCREASE IN NEAR TERM.GSK CEO SAYS HAVING A LOOK AT PFIZER CONSUMER BUSINESS; WE DON'T NEED IT, WOULDN'T OVERPAY FOR IT.  Full Article

GlaxoSmithkLine Acquires Further 26 Pct Stake In Glaxo Saudi Arabia
Monday, 18 Dec 2017 

Dec 18 (Reuters) - GLAXOSMITHKLINE ::ACQUIRES ADDITIONAL 26 PERCENT STAKE IN GLAXO SAUDI ARABIA LIMITED‍​.INTENDS TO EXPAND PRODUCTION OF JEDDAH MANUFACTURE SITE BY 30 PERCENT IN NEXT 3 YEARS WITH MORE INVESTMENTS TO BE DONE BY 2020‍​.SAYS "ACQUISITION IS COMING ON TOP OF MORE THAN SAR 900 MILLION THAT GSK IS INVESTING IN ITS OPERATION IN SAUDI OVER NEXT 3 YEARS‍​".SAYS "BY INCREASING STAKE IN GSAL, GSK REITERATES COMMITMENT TO SUPPORT SAUDI GOVERNMENT PLANS TO DIVERSIFY ECONOMY ‍".  Full Article

Glaxosmithkline Submits Regulatory Application For Single-Dose Tafenoquine For Treatment Of Plasmodium Vivax Malaria
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Glaxosmithkline Plc ::SUBMITS REGULATORY APPLICATION FOR SINGLE-DOSE TAFENOQUINE FOR TREATMENT OF PLASMODIUM VIVAX MALARIA TO AUSTRALIA'S THERAPEUTIC GOODS ADMINISTRATION​.GSK PLANS TO PROGRESS REGULATORY FILINGS IN OTHER COUNTRIES IN 2018‍​.  Full Article

U.S. FDA Approves First Drug For Eosinophilic Granulomatosis With Polyangiitis
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - U.S. Food and Drug Administration::SAYS EXPANDED APPROVED USE OF NUCALA (MEPOLIZUMAB) TO TREAT ADULT PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS‍.SAYS GRANTED APPROVAL OF NUCALA TO GLAXOSMITHKLINE.  Full Article

Glaxosmithkline Says ‍New Data From Phase III Clinical Study Supports Safety And Efficacy
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Glaxosmithkline Plc ::‍NEW DATA FROM A PHASE III CLINICAL STUDY SUPPORTS SAFETY AND EFFICACY OF SHINGRIX IN PREVENTING SHINGLES​.ZOE-HSCT STUDY SUCCEEDED PRIMARY OBJECTIVE BY DEMONSTRATING AN EFFICACY OF 68.17% AGAINST SHINGLES IN SUBJECTS ABOVE 18 YEARS OF AGE​.  Full Article

ACCC Institutes Proceedings Against GSK, Novartis
Tuesday, 5 Dec 2017 

Dec 6 (Reuters) - Australian Competition and Consumer Commission:INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD (GSK) AND NOVARTIS CONSUMER HEALTH AUSTRALASIA.PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.SEEKING DECLARATIONS, INJUNCTIONS, PECUNIARY PENALTIES, A PUBLICATION ORDER, THE IMPOSITION OF A COMPLIANCE PROGRAM AND COSTS.  Full Article

John Wood Group Wins Multi-Million Dollar Contract Supporting Glaxosmithkline In Germany​
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - John Wood Group Plc ::WOOD WINS CONTRACT SUPPORTING GLAXOSMITHKLINE.‍WOOD WINS MULTI-MILLION DOLLAR CONTRACT SUPPORTING GLAXOSMITHKLINE IN GERMANY​.  Full Article

Photo

P&G's vitamin boost could signal more to come

LONDON/CHICAGO Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products.